Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Richard L. Chang is active.

Publication


Featured researches published by Richard L. Chang.


Experimental Biology and Medicine | 1997

Some Perspectives on Dietary Inhibition of Carcinogenesis: Studies with Curcumin and Tea

Allan H. Conney; You-Rong Lou; Jian-Guo Xie; Toshihiko Osawa; Harold L. Newmark; Y. Liu; Richard L. Chang; Mou Tuan Huang

Abstract Topical application of curcumin inhibits chemically induced carcinogenesis on mouse skin, and oral administration of curcumin inhibits chemically induced oral, forestomach, duodenal, and colon carcinogenesis. Curcumin and other inhibitors of cyclooxygenase and lipoxygenase are thought to inhibit carcinogenesis by preventing the formation of arachidonic acid metabolites. In contrast to our expectation of a tumorigenic effect of arachidonic acid, we found that treatment of 7,12-dimethyl-benz[a]anthracene-initiated mouse skin with very high doses of arachidonic acid twice daily, 5 days a week for 26 weeks, failed to result in tumors. We considered the possibility that some of the cancer chemopreventive effects of curcumin may be related to an effect of this compound on cellular differentiation, and we investigated the effect of curcumin on differentiation in the human promyelocytic HL-60 leukemia cell model system. Although curcumin alone had little or no effect on cellular differentiation, when it was combined with all-trans retinoic acid or 1α,25-dihydroxyvitamin D3 a synergistic effect was observed. It is possible that many dietary chemicals in fruits, vegetables, and other edible plants can prevent cancer by synergizing with endogenously produced stimulators of differentiation such as all-trans retinoic acid, 1α,25-dihydroxyvitamin D3, and butyrate. More research is needed to test this hypothesis Administration of green or black tea inhibits carcinogenesis in several animal models, and tumor growth is also inhibited. Several examples were presented of chemopreventive agents that inhibit carcinogenesis in one animal model but enhance carcinogenesis in a different animal model. Greater efforts should be made to understand mechanisms of cancer chemoprevention and to determine whether a potential chemopreventive agent is useful in many experimental settings or whether it is useful in only a limited number of experimental settings.


Advances in Experimental Medicine and Biology | 2001

Dose-dependent differences in the profile of mutations induced by carcinogenic (R,S,S,R) bay- and fjord-region diol epoxides of polycyclic aromatic hydrocarbons.

Allan H. Conney; Richard L. Chang; Xiao Xing Cui; Maria Schiltz; Haruhiko Yagi; Donald M. Jerina; Shu-Jing C. Wei

Chinese hamster V79 cells were exposed to a high or low concentration of the highly carcinogenic (R,S,S,R) or the less active (S,R,R,S) bay- or fjord-region diol epoxides of benzo[a]pyrene, benzo[c]phenanthrene or dibenz[c,h]acridine. Independent 8-azaguanine-resistant clones were isolated, and base substitutions at the hypoxanthine (guanine) phosphoribosyltransferase (hprt) locus were determined. For the three (R,S,S,R) diol epoxides studied, the proportion of mutations at AT base pairs increased as the concentration of diol epoxide decreased. Concentration-dependent differences in the mutational profile were not observed, however, for the three (S,R,R,S) diol epoxides. In studies, with V-H1 cells (a DNA repair deficient variant of V79 cells), a concentration-dependent difference in the profile of mutations for the (R,S,S,R) diol epoxide of benzo[a]pyrene was not observed. These results suggest that concentration-dependent differences in the mutational profile are dependent on an intact DNA repair system. In additional studies, we initiated mouse skin with a high or low dose of benzo[a]pyrene and promoted the mice for 26 weeks with 12-O-tetradecanoylphorbol-13-acetate. Papillomas were examined for mutations in the c-Ha-ras proto-oncogene. Dose-dependent differences in the profile of c-Ha-ras mutations in the tumors were observed. In summary, (i) dose-dependent differences in mutational profiles at the hprt locus were observed in Chinese hamster V79 cells treated with several highly mutagenic and carcinogenic (R,S,S,R) bay- or fjord-region diol epoxides but not with their less active (S,R,R,S) diol epoxide enantiomers, (ii) a dose-dependent difference in the mutational profile was not observed for the (R,S,S,R) diol epoxide of benzo[a]pyrene in a DNA-repair defective V79 cell line, and (iii) a dose-dependent difference in the mutational profile in the c-Ha-ras proto-oncogene was observed in tumors from mice treated with a high or low dose of benzo[a]pyrene.


International Journal of Molecular Medicine | 2015

Combination of 12-O-tetradecanoylphorbol-13-acetate with diethyldithiocarbamate markedly inhibits pancreatic cancer cell growth in 3D culture and in immunodeficient mice

Huarong Huang; Kajia Cao; Saquib Malik; Qiuyan Zhang; Dongli Li; Richard L. Chang; Huaqian Wang; Weiping Lin; Jeremiah Van Doren; Kun Zhang; Zhiyun Du; Xi Zheng

The aim of the present study was to determine the effects of 12-O-tetradecanoylphorbol-13-acetate (TPA) and diethyldithiocarbamate (DDTC) alone or in combination on human pancreatic cancer cells cultured in vitro and grown as xenograft tumors in nude mice. Pancreatic cancer cells were treated with either DDTC or TPA alone, or in combination and the number of viable cells was then determined by trypan blue ecxlusion assay and the number of apoptotic cells was determined by morphological assessment by staining the cells with propidium idiode and examining them under a fluorescence microscope. Treatment with DDTC or TPA alone inhibited the growth and promoted the apoptosis of pancreatic cancer cells in a concentration-dependent manner. These effects were more prominent following treatment with TPA in combination with DDTC than following treatment with either agent alone in PANC-1 cells in monolayer cultures and in 3 dimensional (3D) cultures. The potent effects of the combination treatment on PANC-1 cells were associated with the inhibition of nuclear factor-κB (NF-κB) activation and the decreased expression of Bcl-2 induced by DDTC, as shown by NF-κB-dependent reporter gene expression assay and western blot analysis. Furthermore, treatment of nude mice with DDTC + TPA strongly inhibited the growth of PANC-1 xenograft tumors. The results of the present study indicate that the administration of TPA and DDTC in combination may be an effective strategy for inhibiting the growth of pancreatic cancer.


Carcinogenesis | 2013

Mutagenicity and tumorigenicity of the four enantiopure bay-region 3,4-diol-1,2-epoxide isomers of dibenz[ a , h ]anthracene

Richard L. Chang; Alexander W. Wood; Mou-Tuan Huang; Jian Guo Xie; Xiao Xing Cui; Kenneth R. Reuhl; Derek R. Boyd; Yong Lin; Weichung Joe Shih; Suresh K. Balani; Harujiko Yagi; Donald M. Jerina; Allan H. Conney

Each enantiomer of the diastereomeric pair of bay-region dibenz[a,h]anthracene 3,4-diol-1,2-epoxides in which the benzylic 4-hydroxyl group and epoxide oxygen are either cis (isomer 1) or trans (isomer 2) were evaluated for mutagenic activity. In strains TA 98 and TA 100 of Salmonella typhimurium, the diol epoxide with (1S,2R,3S,4R) absolute configuration [(-)-diol epoxide-1] had the highest mutagenic activity. In Chinese hamster V-79 cells, the diol epoxide with (1R,2S,3S,4R) absolute configuration [(+)-diol epoxide-2] had the highest mutagenic activity. The (1R,2S,3R,4S) diol epoxide [(+)-diol epoxide-1] also had appreciable activity, whereas the other two bay-region diol epoxide enantiomers had very low activity. In tumor studies, the (1R,2S,3S,4R) enantiomer was the only diol epoxide isomer tested that had strong activity as a tumor initiator on mouse skin and in causing lung and liver tumors when injected into newborn mice. This stereoisomer was about one-third as active as the parent hydrocarbon, dibenz[a,h]anthracene as a tumor initiator on mouse skin; it was several-fold more active than dibenz[a,h]anthracene as a lung and liver carcinogen when injected into newborn mice. (-)-(3R,4R)-3β,4α-dihydroxy-3,4-dihydro-dibenz[a,h]anthracene [(-)-3,4-dihydrodiol] was slightly more active than dibenz[a,h]anthracene as a tumor initiator on mouse skin, whereas (+)-(3S,4S)-3α,4β-dihydroxy-3,4-dihydro-dibenz[a,h]anthracene [(+)-3,4-dihydrodiol] had only very weak activity. The present investigation and previous studies with the corresponding four possible enantiopure bay-region diol epoxide enantiomers/diastereomers of benzo[a]pyrene, benz[a]anthracene, chrysene, benzo[c]phenanthrene, dibenz[c,h]acridine, dibenz[a,h]acridine and dibenz[a,h]anthracene indicate that the bay-region diol epoxide enantiomer with [R,S,S,R] absolute stereochemistry has high tumorigenic activity on mouse skin and in newborn mice.


Polycyclic Aromatic Compounds | 1999

Synthesis and Properties of Bay-Region Episulfides of Benzo[a]Pyrene

Haruhiko Yagi; Sreenivasarao Vepachedu; Jane M. Sayer; Richard L. Chang; Xiao-xing Cui; Uri Zoller; Donald M. Jerina

Abstract A highly efficient, general method was developed for conversion of epoxides to the corresponding episulfides with dimethylthioformamide in the presence of BF3Et2O at low temperature (-20°C). Thus, the 9,10-epoxide of 7,8,9,10-tetrahydrobenzo[a]pyrene (3) and 4-methoxystyrene oxide (6) were converted to the corresponding episulfides (4) and (7), respectively, in over 90% yield. Highly stereoselective conversions of (±)-7β,8α-dihydroxy-9β, 10β-epoxy-7,8,9, 10-tetrahydrobenzo[a]pyrene (DE-1, 1a) and its diastereomeric 9,10-isomer (DE-2, 2a) to the corresponding diol episulfide-2b (DES-2) and -1b (DES-1), respectively, were also achieved by this method. These episulfides showed remarkable stability towards aqueous acid (>105 less reactive than the corresponding epoxides). Studies in Chinese hamster V-79 cells indicated that 1b and 2b have very low toxicity and mutagenicity compared to 2a.


Drug Metabolism Reviews | 1994

Studies on the Metabolism of Benzo[a]Pyrene and Dose-Dependent Differences in the Mutagenic Profile of Its Ultimate Carcinogenic Metabolite

Allan H. Conney; Richard L. Chang; Donald M. Jerina; S.-J. C. Wei


Carcinogenesis | 1993

Inhibitory effect of curcumin on 12-O-tetradecanoylphorbol-13-acetate-induced increase in ornithine decarboxylase mRNA in mouse epidermis

Yao-Ping Lu; Richard L. Chang; Mou-Tuan Huang; Allan H. Conney


Carcinogenesis | 1994

Mutagenic selectivity at the HPRT locus in V-79 cells: comparison of mutations caused by bay-region benzo[a]pyrene 7,8-diol-9,10-epoxide enantiomers with high and low carcinogenic activity

S.-J.C. Wei; Richard L. Chang; E. Hennig; Xiao Xing Cui; Kathleen A. Merkler; Ching-Quo Wong; Haruhiko Yagi; Donald M. Jerina; Allan H. Conney


Cancer Chemotherapy and Pharmacology | 2006

A phase I clinical trial of 12- O-tetradecanoylphorbol-13-acetate for patients with relapsed/refractory malignancies

Dale G. Schaar; Lauri Goodell; Joseph Aisner; Xiao Xing Cui; Zheng Tao Han; Richard L. Chang; John Martin; Stephanie Grospe; Liesel Dudek; Joan Riley; Jacqueline Manago; Yong Lin; Eric H. Rubin; Allan H. Conney; Roger Strair


Carcinogenesis | 1999

Dose-dependent mutation profile in the c-Ha-ras proto-oncogene of skin tumors in mice initiated with benzo[a]pyrene

Shu Jing Caroline Wei; Richard L. Chang; Kathleen A. Merkler; Mark Gwynne; Xiao Xing Cui; Bindu Murthy; Mou Tuan Huang; Jian Guo Xie; Yao Ping Lu; You Rong Lou; Donald M. Jerina; Allan H. Conney

Collaboration


Dive into the Richard L. Chang's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar

Donald M. Jerina

National Institutes of Health

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Haruhiko Yagi

National Institutes of Health

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Jane M. Sayer

National Institutes of Health

View shared research outputs
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge